Mineralys Therapeutics Inc. Gains 42.21%
Mon, Mar 10, 2025 at 08:11 PM
Mineralys Therapeutics Inc. (MLYS:NASDAQ) rocketted at $14.96, a gain of 42.2%. On Mon, Mar 10, 2025, MLYS:NASDAQ hit a New 2-Week High of $14.96. The stock appeared on our News Catalysts scanner on Mon, Mar 10, 2025 at 06:41 PM in the 'PUBLIC OFFERING' category. From Mon, Feb 24, 2025, the stock recorded 60.00% Up Days and 54.55% Green Days
About Mineralys Therapeutics Inc. (MLYS:NASDAQ)
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.
Top 10 Gainers:
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 176.92%
- Heidmar Maritime Holdings Corp. (HMR:NASDAQ), 69.54%
- Redfin Corporation (RDFN:NASDAQ), 67.87%
- Checkpoint Therapeutics, Inc. (CKPT:NASDAQ), 61.13%
- Sharps Technology Inc. (STSS:NASDAQ), 48.3%
- Protagonist Therapeutics, Inc. (PTGX:NASDAQ), 45.89%
- Bally's Corporation (BALY:NYSE), 42.74%
- Mineralys Therapeutics Inc. (MLYS:NASDAQ), 42.21%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 41.16%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 39.5%